You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Todos said it intends to use part of the proceeds to retire outstanding convertible notes and complete the acquisition of Provista Diagnostics.
The company's two largest investors will purchase $25 million of its common shares, with proceeds supporting ongoing test commercialization.
The funding will be used to validate the Simplexa COVID-19 Direct kit and Simplexa COVID-19 & Flu A/B Direct kit and to submit them to the FDA for 510(k) clearance.
The company said it will use the financing to further develop its Transistor molecular detection platform and significantly expand mass manufacturing.
The company plans to use to the funds to accelerate the commercialization of its CRISPRclean technology and expand into additional markets.
The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.
Evorion also closed a financing round for an undisclosed amount, and Jüke has become a shareholder in the company.
Ovation offers laboratory information management system and laboratory information system software for molecular diagnostic test development.
The funding will help the company further develop its INSPECTR molecular diagnostic platform into a test that can be used in various settings.
The firm said it will use the financing for ongoing development of software and learning models.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.